Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition ...
At the event, journalists, lawyers and former ministers remembered the late AG Noorani's 'sense of justice', and his talents as a methodical chronicler.
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)今日宣布停止开发用于治疗与精神分裂症相关的认知障碍的luvadaxistat,原因是该化合物在ERUDITE二期临床研究中未能达到主要终点。此决定是在与先前显示出希望的INTERACT研究结果不一致后做出的。 ERUDITE试验未能重现先前的认知改善结果,这被归因于认知测量的显著变异性以及研 ...
12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to ...
The Victorian Supreme Court proceedings involving People Shop, which traded as Euridite Legal, have been plagued with hindered disciplinary proceedings, baseless allegations levelled at practitioners ...